Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 24, 2022, Ultragenyx Pharmaceutical Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). As of the record date of April 26, 2022, 69,871,583 shares of the Company's common stock were outstanding and entitled to vote at the Annual Meeting. A total of 67,140,757 shares of the Company's common stock were represented in person or by proxy at the Annual Meeting.

Proposal No. 1 - Election of Class III Directors

At the Annual Meeting, the Company's stockholders elected the Class III director nominees below to the Company's Board of Directors to hold office until the 2025 Annual Meeting of Stockholders or until their successors are elected. The votes on Proposal 1 were as follows:



Class III Director Nominees Votes For  Votes Withheld Broker Non-Votes
Lars Ekman, M.D., Ph.D.     63,976,281 758,889        2,405,587
Matthew K. Fust             63,142,267 1,592,903      2,405,587
Amrit Ray, M.D.             64,377,587 357,583        2,405,587

Proposal No. 2 - Ratification of Selection of Independent Registered Accounting Firm

At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022. The votes on Proposal 2 were as follows:



Votes For  Votes Against Abstentions
66,724,191 406,563       10,003

Proposal No. 3 - Advisory (Non-Binding) Vote to Approve Executive Compensation

At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its "named executive officers" as described in the Proxy Statement. The votes on Proposal 3 were as follows:

Votes For Votes Against Abstentions Broker Non-Votes 57,125,366 7,592,307 17,497 2,405,587

Proposal No. 4 - Advisory (Non-Binding) Vote on Frequency of Advisory Vote on Executive Compensation

At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of the frequency of future advisory votes on approving the compensation the Company pays to its "named executive officers" as described in the Proxy Statement. The votes on Proposal 4 were as follows:



One Year   Two years Three Years Abstain
64,214,557 4,517     500,690     15,406

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses